Change
Tools: Print this page Recommend this page

Consolidated statement of income


 

3RD QUARTER

 

IN € MILLIONS

JANUARY - SEPTEMBER

 

2010

20091

 

 

2010

20091

1

Restated for comparative presentation.

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

 

 

3,867

3,425

 

Revenue

11,020

9,940

 

(2,277)

(2,060)

 

Cost of sales

(6,442)

(5,962)

 

1,590

1,365

 

Gross profit

4,578

3,978

 

 

 

 

 

 

 

 

(853)

(786)

 

Selling expenses

(2,484)

(2,308)

 

(275)

(236)

 

General and administrative expenses

(789)

(766)

 

(89)

(81)

 

Research and development expenses

(251)

(244)

 

8

84

 

Other operating income/(expenses)

6

107

 

381

346

 

Operating income

1,060

767

 

 

 

 

 

 

 

 

(70)

(97)

 

Net financing expenses

(271)

(287)

 

9

6

 

Results from associates and joint ventures

21

16

 

320

255

 

Profit before tax

810

496

 

 

 

 

 

 

 

 

(81)

(32)

 

Income tax

(210)

(108)

 

239

223

 

Profit for the period from continuing operations

600

388

 

 

 

 

 

 

 

 

 

 

 

Discontinued operations

 

 

 

21

(4)

 

Profit for the period from discontinued operations

58

17

 

 

 

 

 

 

 

 

260

219

 

Profit for the period

658

405

 

 

 

 

 

 

 

 

 

 

 

Attributable to:

 

 

 

238

197

 

- Shareholders of the company

592

345

 

22

22

 

- Minority interests

66

60

 

 

 

 

 

 

 

 

260

219

 

Profit for the period

658

405

 

 

 

 

 

 

 

 

 

 

 

Earnings per share from continuing operations (in €):

 

 

 

0.93

0.87

 

- Basic

2.29

1.42

 

0.92

0.86

 

- Diluted

2.27

1.41

 

 

 

 

 

 

 

 

 

 

 

Earnings per share from discontinued operations (in €):

 

 

 

0.09

(0.02)

 

- Basic

0.25

0.07

 

0.09

(0.02)

 

- Diluted

0.25

0.07

 

 

 

 

 

 

 

 

 

 

 

Earnings per share from total operations (in €):

 

 

 

1.02

0.85

 

- Basic

2.54

1.49

 

1.01

0.84

 

- Diluted

2.52

1.48

Copyright © 2010 Akzo Nobel N.V.